← All trials
NCT04467086
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 11, 2020
- Primary completion
- Apr 30, 2021
- Completion date
- May 31, 2021
- First posted
- Jul 10, 2020
- Last posted
- Dec 17, 2020
- Enrollment
- 108
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of OttawaLead sponsor
- Hamilton Health Sciences CorporationCollaborator
- McMaster UniversityCollaborator
- University of OttawaCollaborator
- University of OttawaOverall official - principal investigator
- Sinai Health SystemCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.